NCT00274651

A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 53 (actual)
• Sponsor: Valerio Therapeutics · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Open-label, non-randomized trial to assess the effectiveness of PXD101 in patients with recurrent or refractory cutaneous or peripheral and other types of T-cell lymphomas. PXD101 is a new, potent histone deacetylase (HDAC) inhibitor. Patients are treated with belinostat(PXD101) 1000 mg/m2 on days 1-5 of a 21 day cycle.

Conditions

• Cutaneous T-Cell Lymphoma
• Peripheral T-Cell Lymphoma
• Non-Hodgkin's Lymphoma

Interventions

Type	Name	Description
DRUG	belinostat

Timeline

• Start date: 2006-01-01
• Primary completion: 2009-07-01
• Completion: 2009-07-01
• First posted: 2006-01-11
• Last updated: 2015-07-28
• Results posted: 2014-10-27

Locations

15 sites across 5 countries: United States, France, Germany, Israel, Thailand